{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["121(12)"],"submitter":["Darlix A"],"funding":["This work was supported by R&amp;D UNICANCER. The ESME MBC database is supported by an industrial consortium"],"pubmed_abstract":["<h4>Background</h4>Metastatic breast cancer (MBC) behaviour differs depending on hormone receptors (HR) and human epidermal growth factor receptor (HER2) statuses.<h4>Methods</h4>The kinetics of central nervous system (CNS) metastases (CNS metastasis-free survival, CNSM-FS) and subsequent patient's prognosis (overall survival, OS) according to the molecular subtype were retrospectively assessed in 16703 MBC patients of the ESME nationwide multicentre MBC database (Kaplan-Meier method).<h4>Results</h4>CNS metastases occurred in 4118 patients (24.6%) (7.2% at MBC diagnosis and 17.5% later during follow-up). Tumours were HER2-/HR+ (45.3%), HER2+/HR+ (14.5%), HER2+/HR- (14.9%) and triple negative (25.4%). Median age at CNS metastasis diagnosis was 58.1 years (range: 22.8-92.0). The median CNSM"],"journal":["British journal of cancer"],"pagination":["991-1000"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6964671"],"repository":["biostudies-literature"],"pubmed_title":["Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort."],"pmcid":["PMC6964671"],"pubmed_authors":["Chevrot M","Levy C","Louvel G","Pasquier D","Ferrero JM","Uwer L","Brain E","Robain M","Leheurteur M","Cottu P","Darlix A","Campone M","Lecouillard I","Augereau P","Goncalves A","Dalenc F","Dieras V","Jacot W","Fraisse J","Debled M","Mouret-Reynier MA","Fumet JD","Bachelot T","Petit T","Jouannaud C","Delaloge S"],"additional_accession":[]},"is_claimable":false,"name":"Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort.","description":"<h4>Background</h4>Metastatic breast cancer (MBC) behaviour differs depending on hormone receptors (HR) and human epidermal growth factor receptor (HER2) statuses.<h4>Methods</h4>The kinetics of central nervous system (CNS) metastases (CNS metastasis-free survival, CNSM-FS) and subsequent patient's prognosis (overall survival, OS) according to the molecular subtype were retrospectively assessed in 16703 MBC patients of the ESME nationwide multicentre MBC database (Kaplan-Meier method).<h4>Results</h4>CNS metastases occurred in 4118 patients (24.6%) (7.2% at MBC diagnosis and 17.5% later during follow-up). Tumours were HER2-/HR+ (45.3%), HER2+/HR+ (14.5%), HER2+/HR- (14.9%) and triple negative (25.4%). Median age at CNS metastasis diagnosis was 58.1 years (range: 22.8-92.0). The median CNSM","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Dec","modification":"2026-05-07T02:55:27.67Z","creation":"2020-11-19T11:38:10Z"},"accession":"S-EPMC6964671","cross_references":{"pubmed":["31719684"],"doi":["10.1038/s41416-019-0619-y"]}}